200 related articles for article (PubMed ID: 27709139)
1. The suppression of metastatic lung cancer by pulmonary administration of polymer nanoparticles for co-delivery of doxorubicin and Survivin siRNA.
Xu C; Tian H; Wang P; Wang Y; Chen X
Biomater Sci; 2016 Oct; 4(11):1646-1654. PubMed ID: 27709139
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer.
Xu C; Wang P; Zhang J; Tian H; Park K; Chen X
Small; 2015 Sep; 11(34):4321-33. PubMed ID: 26136261
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Lysosomal Escape of pH-Responsive Polyethylenimine-Betaine Functionalized Carbon Nanotube for the Codelivery of Survivin Small Interfering RNA and Doxorubicin.
Cao Y; Huang HY; Chen LQ; Du HH; Cui JH; Zhang LW; Lee BJ; Cao QR
ACS Appl Mater Interfaces; 2019 Mar; 11(10):9763-9776. PubMed ID: 30776886
[TBL] [Abstract][Full Text] [Related]
4. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
5. Novel functionalized nanoparticles for tumor-targeting co-delivery of doxorubicin and siRNA to enhance cancer therapy.
Xia Y; Xu T; Wang C; Li Y; Lin Z; Zhao M; Zhu B
Int J Nanomedicine; 2018; 13():143-159. PubMed ID: 29317822
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary delivery by exploiting doxorubicin and cisplatin co-loaded nanoparticles for metastatic lung cancer therapy.
Xu C; Wang Y; Guo Z; Chen J; Lin L; Wu J; Tian H; Chen X
J Control Release; 2019 Feb; 295():153-163. PubMed ID: 30586598
[TBL] [Abstract][Full Text] [Related]
7. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticles of pH-Responsive, PEG-Doxorubicin Conjugates: Interaction with an in Vitro Model of Lung Adenocarcinoma and Their Direct Formulation in Propellant-Based Portable Inhalers.
Rao KSVK; Zhong Q; Bielski ER; da Rocha SRP
Mol Pharm; 2017 Nov; 14(11):3866-3878. PubMed ID: 28972765
[TBL] [Abstract][Full Text] [Related]
9. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy of Breast Cancer by Codelivery of Doxorubicin and Survivin siRNA Using Polyethylenimine Modified Silk Fibroin Nanoparticles.
Norouzi P; Motasadizadeh H; Atyabi F; Dinarvand R; Gholami M; Farokhi M; Shokrgozar MA; Mottaghitalab F
ACS Biomater Sci Eng; 2021 Mar; 7(3):1074-1087. PubMed ID: 33539074
[TBL] [Abstract][Full Text] [Related]
11. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug.
Garbuzenko OB; Saad M; Betigeri S; Zhang M; Vetcher AA; Soldatenkov VA; Reimer DC; Pozharov VP; Minko T
Pharm Res; 2009 Feb; 26(2):382-94. PubMed ID: 18958402
[TBL] [Abstract][Full Text] [Related]
12. Co-Delivery of Doxorubicin and Survivin shRNA-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.
Li Z; Zhang L; Tang C; Yin C
Pharm Res; 2017 Dec; 34(12):2829-2841. PubMed ID: 28948461
[TBL] [Abstract][Full Text] [Related]
13. Hyperbranched-hyperbranched polymeric nanoassembly to mediate controllable co-delivery of siRNA and drug for synergistic tumor therapy.
Jia HZ; Zhang W; Zhu JY; Yang B; Chen S; Chen G; Zhao YF; Feng J; Zhang XZ
J Control Release; 2015 Oct; 216():9-17. PubMed ID: 26272764
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of doxorubicin and interleukin-2 via chitosan based nanoparticles for enhanced antitumor efficacy.
Wu J; Tang C; Yin C
Acta Biomater; 2017 Jan; 47():81-90. PubMed ID: 27729232
[TBL] [Abstract][Full Text] [Related]
15. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy.
Zhu QL; Zhou Y; Guan M; Zhou XF; Yang SD; Liu Y; Chen WL; Zhang CG; Yuan ZQ; Liu C; Zhu AJ; Zhang XN
Biomaterials; 2014 Jul; 35(22):5965-76. PubMed ID: 24768047
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
[TBL] [Abstract][Full Text] [Related]
17. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells.
Dong DW; Xiang B; Gao W; Yang ZZ; Li JQ; Qi XR
Biomaterials; 2013 Jul; 34(20):4849-59. PubMed ID: 23541420
[TBL] [Abstract][Full Text] [Related]
18. Folate-decorated PEGylated triblock copolymer as a pH/reduction dual-responsive nanovehicle for targeted intracellular co-delivery of doxorubicin and Bcl-2 siRNA.
Suo A; Qian J; Xu M; Xu W; Zhang Y; Yao Y
Mater Sci Eng C Mater Biol Appl; 2017 Jul; 76():659-672. PubMed ID: 28482576
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of doxorubicin and siRNA for glioma therapy by a brain targeting system: angiopep-2-modified poly(lactic-co-glycolic acid) nanoparticles.
Wang L; Hao Y; Li H; Zhao Y; Meng D; Li D; Shi J; Zhang H; Zhang Z; Zhang Y
J Drug Target; 2015; 23(9):832-46. PubMed ID: 25856302
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor efficacy of arginine modified amphiphilic nanoparticles co-delivering doxorubicin and iSur-pDNA via the multiple synergistic effect.
Song Y; Tang C; Yin C
Biomaterials; 2018 Jan; 150():1-13. PubMed ID: 29028548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
